2026Q1 Tempus AI (TEM)

Tempus AI, Inc. (NASDAQ: TEM) represents a critical nexus in the modern biotechnology landscape, operating at the intersection of generative artificial intelligence, next-generation genomic sequencing, and precision medicine. By systematically aggregating and harmonizing one of the world's largest libraries of multimodal healthcare data—surpassing 500 petabytes of clinical, molecular, and imaging records—Tempus has entrenched itself as an indispensable foundational layer for the global pharmaceutical industry. The enterprise operates through a highly synergistic, dual-engine business model. The physical Diagnostics segment acts as a data-ingestion funnel, processing oncology, hereditary, and minimal residual disease (MRD) assays. The resulting longitudinal patient data is subsequently anonymized and transferred to the high-margin Data and Applications segment, where it is licensed to biopharmaceutical giants for algorithmic modeling, biomarker discovery, and clinical trial optimization.As of the first quarter of 2026, Tempus has demonstrated explosive top-line momentum, reporting $348.1 million in quarterly revenue, representing a 36.1% year-over-year expansion.1 The company ended fiscal year 2025 with $1.27 billion in revenue and maintains a Total Contract Value (TCV) backlog exceeding $1.1 billion, underscored by a net revenue retention rate of 126%.2 However, beneath this hyper-growth narrative lie complex fundamental vulnerabilities. The firm continues to operate at a substantial GAAP net loss, reporting a $125.9 million deficit in Q1 2026 alone, heavily skewed by stock-based compensation, aggressive acquisition accounting, and immense research and development expenditures.1This podcast provides an evidence-based fundamental and technical evaluation of Tempus AI. The analysis relies on stringent extraction of 10-K and 10-Q SEC filings, comprehensive 5-year and 8-quarter financial trend analyses, capital allocation evaluations utilizing the Bruce Greenwald methodology, and an assessment of technical market indicators and options flow. Furthermore, the report synthesizes the profound impacts of the 2025-2026 macroeconomic environment—specifically detailing the Trump administration's tariff escalations and domestic healthcare AI deregulation—evaluates top competitors, applies Warren Buffett’s investing criteria to the firm’s economic moat, and scrutinizes recent sell-side analyst sentiment.